Your shopping cart is currently empty

GprA, a novel synthetic agonist for G Protein-Coupled Receptor 120/Free Fatty Acid Receptor 4 (GPR120/FFAR4), demonstrates an AC50 of 203 nM on the full-length human GPR120 isoform. It is valuable for research into non-alcoholic fatty liver disease (NAFLD).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | GprA, a novel synthetic agonist for G Protein-Coupled Receptor 120/Free Fatty Acid Receptor 4 (GPR120/FFAR4), demonstrates an AC50 of 203 nM on the full-length human GPR120 isoform. It is valuable for research into non-alcoholic fatty liver disease (NAFLD). |
| In vivo | GprA effectively reduces signs of fatty degeneration in mice fed with a Western-style diet (WSD). It also plays a significant role in decreasing collagen deposition and the progression of fibrosis. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.